From: Dave Aronberg on 06/24/2002 02:50 PM

To: jon. sale@lawyers. corn
cc: Phil CECE Dave Aronberg/OAG@OAG Jack 

I Subject: Documents

Dear Jon: As we discuswsed we are in need of the following additional documents in our
investigation of Purdue Pharma re: OxyContin Please let me know if you will have any
problems producing these documents 1n a timely manner.

Sincerely,

Dav-e Aronberg

Please produce:-

The names, addresses, phone numbers, titles and job descriptions for your sales personnel

in Florida Who
supervised, trained or otherwise informed physicians on the prescribing or use of

OxyContin.

All marketing and launch for OxyContin, excluding the OxyContin Launch'Plan dated

September 27,
1995 previously produced to the Florida Attorney General.

3\ All documents relating to the commission, rebate and bonus struCtures for your sales

personnel relating to 
the sale of OxyContin. - Qt) 

The names, addresses, phone numbers, titles and job descriptions for your employees or

independent
contractors who authored, revised or approved the text of your warning labels or package

inserts for
OxyContin.

Vf A true copy of your publication entitled Guide to Your New Pain Medicine and How

to Become a
Partner against Pain."

Documents that show the revenue, sales, pro?ts and costs for OxyContin in United States

dollars from . January 1, 1996 to December 31, 1997.
mails relating to abuse-resist ant narc tic pills, also knOwn as "hard pills" or "smart
pills." Maggi-k1? WW

The abbreviation, code name or company identi?er for you in the "2000 Sales Force

AP

 

 

  

7

Effectiveness Study I
Compensation Report" published by the Hay Group Pharmaceutical Industry.

- For the video tape entitled "From One Pain Patient to Another":

21) All participants by physical description, name, address and telephone number.
b) All persons involved in the ?lming production, scripting and promotion ofthe ?lm.
0) The dates of ?lming. 
d) The location where the ?lming took place.
- e) . Any monies, fees, gifts or other arrangements for personal gain received by any or all
0 .
individuals involved.
f) The number of copies made of the ?lm, and state how it was distributed



 

 

 

..

 

m1?c 
41-93 ?MilPt? 21;:me


[ot?sdpp?v

 

 

 

1. Moamg 51E

MA (9 m5 Cuc?h MAW ?aw/1211b nu 
?vaKvawM?fOWbdf?deww/
M12111 LAW #2 it

M11 WW m? (EMA *hw re?m Wm
max-514341 mad/?mq?j?N 

WA 12M 1% +0me 
:6 atria/M111. 

1, 10 102m m5 Mm 111 04 Mum.

 

 

 

 

?455%qu PLMJ Wu?m

My 5

.- mt mm 0.9-
. MUis r6104} . 
3% WW

  

@wa mime WW cuimu.
meb 5255 
Th. pr?o?i?d? MWJ: aux Laser-Q Md U.
with
@100ch PW 12MB ?_ffing?P WM 509m Sand 25.4

 

 

907 max-m- COWLCL

?f?w?r-ul .. 

 

 

 

 

 

?W?Q??ff 305% ?w?oom #01044
WW 0ka

 

E5 LJCQ )und?; 443 .
001+ .
#?iszL WU Wm roam-2?s

.. Lau? _Kl L1 


. in MM ammo? WMS Mg

~?u0tm em 
,0me Lu 0L Wm +0 ML


0/6 010A fmf?l

M__wwm 

 

 

 

 

 

Ewew?rga . .